[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site
Share this article

Study’s contact

Call center

910 240 3498

Email address

priyanka.varma@iqvia.com

Condition

Advanced Cancer,Breast Cancer,Glioma, Malignant,Head and Neck Cancer,Melanoma,Mesothelioma Peritoneum,Mesotheliomas Pleural,Nsclc,Ovary Cancer,Papillary Thyroid Cancer,Solid Carcinoma,Solid Tumor,Cancer,Cervical Cancer,Colorectal Cancer,DIPG Brain Tumor,Diffuse Midline Glioma, H3 K27M-Mutant,Endometrial Cancer,Esophageal Cancer,Gastric Cancer

Treatment type

Interventional

Investigational product

AMXT1501

Phase

Phase 1/Phase 2

Sponsor

Aminex Therapeutics, Inc.

ClinicalTrials.gov identifier

NCT05500508

Study number

AMXT1501-102

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. IMPORTANT NOTE
  2. Younger 12-17 year old patients are also eligible for this study if they meet the noted DIPG or DMG criteria noted below, which is separate from Patient Diagnosed with Advanced Solid Tumors.
  3. Patients will be eligible for study participation only if they meet ALL the

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site